Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.30 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.30 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.30 |
| ▸ | MC3R | P41968 | 1/20 | 0.30 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.30 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.30 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.30 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10248649 | 0.77 | MAPK13 (0.33) | — | |
| SCHEMBL18510397 | 0.63 | TOP2A (0.40) | — | |
| SCHEMBL23768851 | 0.63 | HTR1A (0.33) | PIK3CDPOLBADORA3CNR1ACHE | |
| SCHEMBL14725431 | 0.62 | — | — | |
| SCHEMBL31696695 | 0.60 | PLK1 (0.44) | — | |
| SCHEMBL20104525 | 0.59 | KDM4E (0.32) | NSD3 | |
| SCHEMBL18510388 | 0.57 | TOP2A (0.31) | — | |
| SCHEMBL1020681 | 0.57 | TDP2 (0.41) | — | |
| SCHEMBL14902045 | 0.56 | PNP (0.46) | NSD3PIK3CDPOLBADORA3CNR1 | |
| SCHEMBL4883832 | 0.56 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180063059-A1 | 2'-FLUORO-6'-METHYLENE CARBOCYCLIC NUCLEOSIDES AND METHODS OF TREATING VIRAL INFECTIONS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2018-03-01 | — | — | US | disclosed |
| US-9700560-B2 | 2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2017-07-11 | — | — | US | disclosed |
| US-9126971-B2 | Anti-viral nucleoside analogs and methods for treating viral infections, especially HIV infections | YALE UNIVERSITY (US) | 2015-09-08 | — | — | US | disclosed |
| US-8946244-B2 | 2′-fluoro-6′methylene carbocyclic nucleosides and methods of treating viral infections | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-8816074-B2 | 2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections | University of Georgia Foundation, Inc. (US) | 2014-08-26 | — | — | US | disclosed |
| US-20140073606-A1 | 2'-FLUORO-6'-METHYLENE CARBOCYCLIC NUCLEOSIDES AND METHODS OF TREATING VIRAL INFECTIONS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2014-03-13 | — | — | US | disclosed |
| US-20130005677-A1 | 2'-FLUORO-6'-METHYLENE CARBOCYCLIC NUCLEOSIDES AND METHODS OF TREATING VIRAL INFECTIONS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2013-01-03 | — | — | US | disclosed |
| US-20120252751-A1 | ANTI-VIRAL NUCLEOSIDE ANALOGS AND METHODS FOR TREATING VIRAL INFECTIONS, ESPECIALLY HIV INFECTIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-10-04 | — | — | US | disclosed |
| US-8193165-B2 | Anti-viral nucleoside analogs and methods for treating viral infections, especially HIV infections | YALE UNIVERSITY (US) | 2012-06-05 | — | — | US | disclosed |
| US-20110244027-A1 | 2'-Fluoro-6'-Methylene Carbocyclic Nucleosides and Methods of Treating Viral Infections | UNIVERSITY OF GEORGIA RESEARCH CENTER (US) | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005677-A1 | 2'-FLUORO-6'-METHYLENE CARBOCYCLIC NUCLEOSIDES AND METHODS OF TREATING VIRAL INFECTIONS | HAVCR2, NT5C3B, HCCS | NSD3 459/4885PIK3CD 532/4885POLB 311/4885 |
| US-20120252751-A1 | ANTI-VIRAL NUCLEOSIDE ANALOGS AND METHODS FOR TREATING VIRAL INFECTIONS, ESPECIALLY HIV INFECTIONS | TYMP, ITPA, SAMHD1 | NSD3 374/4885PIK3CD 1569/4885POLB 16/4885 |
| US-20110244027-A1 | 2'-Fluoro-6'-Methylene Carbocyclic Nucleosides and Methods of Treating Viral Infections | HAVCR2, NT5C3B, HCCS | NSD3 459/4885PIK3CD 532/4885POLB 311/4885 |
| US-20140073606-A1 | 2'-FLUORO-6'-METHYLENE CARBOCYCLIC NUCLEOSIDES AND METHODS OF TREATING VIRAL INFECTIONS | HAVCR2, NT5C3B, HCCS | NSD3 461/4885PIK3CD 488/4885POLB 341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.